Storm op zee dag in dag uit met dit aandeel.
Alsook:
Analysts See $0.01 EPS for Pharming Group N.V. (PHGUF)
August 29, 2018 - By Linda Rogers
Pharming Group N.V. (OTCMKTS:PHGUF) Logo
Analysts expect Pharming Group N.V. (OTCMKTS:PHGUF) to report $0.01 EPS on August, 30.They anticipate $0.07 EPS change or 116.67 % from last quarter’s $-0.06 EPS. PHGUF’s profit would be $5.94 million giving it 39.00 P/E if the $0.01 EPS is correct. After having $0.01 EPS previously, Pharming Group N.V.’s analysts see 0.00 % EPS growth. The stock increased 3.31% or $0.05 during the last trading session, reaching $1.56. About shares traded. Pharming Group N.V. (OTCMKTS:PHGUF) has 0.00% since August 29, 2017 and is . It has underperformed by 12.57% the S&P500.
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for treatment of rare diseases and unmet medical needs. The company has market cap of $927.14 million. The company's lead product is Ruconest , a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It currently has negative earnings. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human Factor VIII, a natural human blood clotting factor for treating Haemophilia A.
---